Stockreport

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

XOMA Corporation  (XOMA) 
Last xoma corporation earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investors.xoma.com/investor-relations
PDF Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with [Read more]